Remission in Children and Adolescents Diagnosed with Attention-Deficit/Hyperactivity Disorder via an Effective and Tolerable Titration Scheme for Osmotic Release Oral System Methylphenidate
Authors:
Open Access
- 1 June 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 22 (3) , 215-225
Abstract
Objectives: The purpose of this study was to identify the optimal dose of osmotic release oral system methylphenidate (OROS-MPH) using a dosage forced-titration scheme to achieve symptomatic remission in children with attention- deficit/hyperactivity disorder (ADHD). We also evaluated the efficacy and safety of, and patient and parent satisfaction with, the change in therapy from immediate-release methylphenidate (IR-MPH) to OROS-MPH over 10 weeks. Method: We recruited 521 children and adolescents aged 6–18 years with an American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) diagnosis of ADHD, who had received IR-MPH treatments (<70 mg/day) for at least 1 month. The treatment, switched from IR-MPH to OROS-MPH according to a conversion scheme, started with a 6-week forced-titration phase of OROS-MPH to achieve symptomatic remission (defined as a score of 0 or 1 for each of the first 18 ADHD items in the Chinese version of the Swanson, Nolan, and Pelham, Version IV [SNAP-IV]), followed by a 4-week maintenance phase. The global ADHD severity and drug side effects of the participants were evaluated. Parents completed the ratings scales for the ADHD-related symptoms. Patient and parent satisfaction for the OROS-MPH treatment was also assessed. Results: Among the 439 participants with ADHD who completed the trial, 290 participants (66.1%) achieved symptomatic remission. The mean dose of OROS-MPH among participants in remission was 36.7 mg (1.08 mg/kg) per day. Increased efficacy, superior satisfaction, and safety equivalent to that of IR-MPH were demonstrated in intra-individual comparisons from the baseline to the end of study. Determinants for remission included less severe ADHD symptoms (SNAP-IV score < 40), no family history of ADHD, and an appropriate dosage of medication according to the patient's weight. Conclusions: The findings suggest remission as a treatment goal for ADHD therapy by providing an optimal dosage of medication for children and adolescents with ADHD through using an effective and tolerable forced-titration scheme.Keywords
This publication has 52 references indexed in Scilit:
- Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studiesChild and Adolescent Psychiatry and Mental Health, 2011
- Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity DisorderCNS Drugs, 2011
- Dose–Response Characteristics in Adolescents with Attention-Deficit/Hyperactivity Disorder Treated with OROS ® Methylphenidate in a 4-Week, Open-Label, Dose-Titration StudyJournal of Child and Adolescent Psychopharmacology, 2010
- Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, version IV scale – parent formInternational Journal of Methods in Psychiatric Research, 2008
- A Prospective 12-Week Study of Quetiapine in Adolescents with Schizophrenia Spectrum DisordersJournal of Child and Adolescent Psychopharmacology, 2007
- A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on Once-Daily Atomoxetine Hydrochloride in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology, 2007
- An Open-Label, Randomized, Active-Controlled Equivalent Trial of Osmotic Release Oral System Methylphenidate in Children with Attention-Deficit/Hyperactivity Disorder in TaiwanJournal of Child and Adolescent Psychopharmacology, 2006
- A Laboratory School Comparison of Mixed Amphetamine Salts Extended Release (Adderall XR®) and Atomoxetine (Strattera®) in School-Aged Children With Attention Deficit/Hyperactivity DisorderJournal of Attention Disorders, 2005
- Global consensus on ADHD/HKDEuropean Child & Adolescent Psychiatry, 2005
- Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled StudyAmerican Journal of Psychiatry, 2002